Boston Scientific Corporation Share Price
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.52 USD | -0.20% |
|
-4.00% | +9.18% |
| 03/12 | Boston Scientific Insider Sold Shares Worth $1,758,189, According to a Recent SEC Filing | MT |
| 03/12 | Aclarion, Inc. Appoints Jason Brosniak as Commercial Director for the Eastern U.S | CI |
| Capitalization | 14TCr 12TCr 12TCr 11TCr 20TCr 13,01100Cr 22TCr 1,36200Cr 53TCr 6,14500Cr 54TCr 53TCr 22,46800Cr | P/E ratio 2025 * |
47.2x | P/E ratio 2026 * | 38x |
|---|---|---|---|---|---|
| Enterprise value | 15TCr 13TCr 12TCr 12TCr 21TCr 13,80700Cr 23TCr 1,44500Cr 56TCr 6,52100Cr 58TCr 56TCr 23,84300Cr | EV / Sales 2025 * |
7.64x | EV / Sales 2026 * | 6.71x |
| Free-Float |
84.69% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Boston Scientific Corporation
| 1 day | -0.20% | ||
| 1 week | -4.00% | ||
| Current month | -4.00% | ||
| 1 month | -1.54% | ||
| 3 months | -9.05% | ||
| 6 months | -4.48% | ||
| Current year | +9.18% |
| 1 week | 97.02 |  | 101.91 |
| 1 month | 95.98 | | 105.65 |
| Current year | 85.98 | | 109.5 |
| 1 year | 85.98 | | 109.5 |
| 3 years | 44.35 | | 109.5 |
| 5 years | 33.42 | | 109.5 |
| 10 years | 15.67 | | 109.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Mahoney
CEO | Chief Executive Officer | 60 | 01/11/2011 |
Jonathan Monson
DFI | Director of Finance/CFO | 51 | 30/06/2025 |
John Sorenson
COO | Chief Operating Officer | 57 | 01/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
John Sununu
BRD | Director/Board Member | 60 | 01/04/2009 |
Michael Mahoney
CHM | Chairman | 60 | 03/05/2016 |
Edward Ludwig
BRD | Director/Board Member | 73 | 01/03/2014 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 1.75% | 26 M€ | +11.73% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.20% | -4.00% | +8.27% | +115.94% | 14TCr | |
| -0.43% | -3.06% | +8.20% | +4.04% | 22TCr | |
| +1.18% | +0.32% | +4.53% | +116.04% | 20TCr | |
| -0.39% | -0.23% | -1.68% | -14.74% | 16TCr | |
| +1.92% | +1.56% | -15.42% | -11.65% | 5.65TCr | |
| +0.48% | -0.55% | +20.49% | +19.26% | 5TCr | |
| -1.91% | -5.22% | +3.49% | -3.87% | 4.12TCr | |
| +3.56% | +6.84% | +5.19% | - | 3.89TCr | |
| +2.00% | +0.28% | +6.27% | +17.83% | 3.74TCr | |
| +1.19% | -0.79% | -22.99% | -37.74% | 3.46TCr | |
| Average | +0.74% | -0.37% | +1.64% | +22.79% | 9.82TCr | |
| Weighted average by Cap. | +0.37% | -1.09% | +3.62% | +40.76% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.01TCr 1.73TCr 1.62TCr 1.51TCr 2.78TCr 1,80700Cr 3.03TCr 19TCr 7.3TCr 85TCr 7.53TCr 7.37TCr 3,12000Cr | 2.24TCr 1.92TCr 1.8TCr 1.68TCr 3.1TCr 2,01300Cr 3.37TCr 21TCr 8.14TCr 95TCr 8.4TCr 8.22TCr 3,47700Cr |
| Net income | 302Cr 259.6Cr 243.19Cr 226.67Cr 418.66Cr 27TCr 455.38Cr 2.84TCr 1.1TCr 13TCr 1.13TCr 1.11TCr 47TCr | 375.86Cr 323.09Cr 302.67Cr 282.11Cr 521.06Cr 34TCr 566.76Cr 3.54TCr 1.37TCr 16TCr 1.41TCr 1.38TCr 58TCr |
| Net Debt | 884.65Cr 760.45Cr 712.38Cr 663.99Cr 1.23TCr 80TCr 1.33TCr 8.33TCr 3.22TCr 38TCr 3.32TCr 3.25TCr 1,37500Cr | 545.28Cr 468.73Cr 439.1Cr 409.27Cr 755.93Cr 49TCr 822.23Cr 5.14TCr 1.98TCr 23TCr 2.05TCr 2TCr 85TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/25/05 | 97.52 $ | -0.20% | 81,45,496 |
| 04/25/04 | 97.72 $ | -0.86% | 94,07,689 |
| 03/25/03 | 98.57 $ | -0.45% | 98,68,971 |
| 02/25/02 | 99.02 $ | -1.97% | 79,77,843 |
| 01/25/01 | 101.01 $ | -0.56% | 56,14,252 |
Delayed Quote Nyse, December 06, 2025 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BSX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition